1. Home
  2. DUO vs SILO Comparison

DUO vs SILO Comparison

Compare DUO & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DUO

Fangdd Network Group Ltd.

HOLD

Current Price

$1.38

Market Cap

7.5M

Sector

Finance

ML Signal

HOLD

Logo Silo Pharma Inc.

SILO

Silo Pharma Inc.

HOLD

Current Price

$0.60

Market Cap

7.2M

ML Signal

HOLD

Company Overview

Basic Information
Metric
DUO
SILO
Founded
2011
2010
Country
China
United States
Employees
N/A
N/A
Industry
Real Estate
Apparel
Sector
Finance
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
7.5M
7.2M
IPO Year
2018
2011

Fundamental Metrics

Financial Performance
Metric
DUO
SILO
Price
$1.38
$0.60
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
33.8K
4.1M
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.98
EPS
N/A
N/A
Revenue
N/A
$72,102.00
Revenue This Year
N/A
$1.86
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.19
$0.22
52 Week High
$5.34
$1.18

Technical Indicators

Market Signals
Indicator
DUO
SILO
Relative Strength Index (RSI) 67.53 66.22
Support Level $1.25 $0.59
Resistance Level $1.78 $0.62
Average True Range (ATR) 0.09 0.07
MACD 0.03 0.02
Stochastic Oscillator 76.51 73.29

Price Performance

Historical Comparison
DUO
SILO

About DUO Fangdd Network Group Ltd.

Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.

About SILO Silo Pharma Inc.

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.

Share on Social Networks: